First reprogramming trial reports early safety data in three glaucoma patients

What the study did

ER-100 is an investigational gene therapy that delivers three reprogramming factors, OCT4, SOX2 and KLF4 (often called OSK), into the eye with a single intravitreal injection. The genes are switched on only while the patient takes oral doxycycline, which in this protocol lasted 8 weeks (56 days). The idea is partial reprogramming: nudging the epigenetic state of aging nerve cells back toward a more youthful pattern without turning them into stem cells.

The open-label Phase 1 trial (NCT07290244) is testing safety in people with optic neuropathies. This interim update covers the first three participants with open-angle glaucoma at the lowest dose. Patients also received a short oral steroid taper to limit an immune reaction to the viral delivery vector.

What it found

According to the company, ER-100 was well tolerated through Day 56 in all three participants. There were no dose-limiting toxicities, no adverse events of special interest and no serious adverse events, and the company attributed the reported adverse events to the injection procedure, steroids or pre-existing conditions.

On Humphrey visual field testing at Day 56, 2 of the 3 participants showed improvement, with at least 28% of tested points improving by more than 4 dB in each of those two people. The independent safety board recommended moving to the next, higher dose level.

What it does not prove

Three patients, no placebo group and 56 days of follow-up cannot establish that ER-100 works, and the company itself states that efficacy cannot be established from these early findings. Visual field tests are known to vary from visit to visit. These results have not yet appeared in a peer-reviewed journal.

Nothing here shows that reprogramming reverses aging in the whole body. ER-100 is delivered locally to the eye, where gene expression can be tightly controlled, which is very different from systemic use.

The Youthful take

This is a genuine first: the idea behind one of the most talked-about areas of longevity science has now been tested in people, and the early safety picture is clean. That is the right first question to answer. We will watch for the higher-dose results, longer follow-up and a peer-reviewed publication before reading much into the vision signal. ER-100 is investigational and is available only inside the clinical trial.